Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects-Reference-Cited by-同舟云学术

Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects

Published:2023-11-28 Issue:1 Volume:63 Page:105-107
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Lasheras‐Pérez Miguel Antonio¹^ORCID,Palacios‐Diaz Rodolfo David¹^ORCID,Pozuelo‐Ruiz Monica¹,Torres‐Navarro Ignacio¹,Botella‐Estrada Rafael¹²,Rodriguez‐Serna Mercedes¹

Affiliation:

1. Department of Dermatology La Fe University and Polytechnic Hospital Valencia Spain

2. Department of Dermatology University of Valencia Valencia Spain

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.16926

Reference12 articles.

1. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

2. Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study

3. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

4. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice

5. Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab;Dermatitis®;2024-08-01

2. Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study);Journal of the European Academy of Dermatology and Venereology;2024-07-17